Resistance mechanisms to methotrexate in tumors

J. R. Bertino, E. Göker, R. Gorlick, W. W. Li, D. Banerjee

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

The mechanisms of intrinsic and acquired resistance to methotrexate (MTX) in human tumors are reviewed herein. In blasts from patients with acute lymphocytic leukemia, resistance mechanisms found are decreased uptake and increased dihydrofolate reductase (DHFR) activity. A major cause of intrinsic resistance to MTX in soft tissue sarcoma cells and in acute myelocytic leukemia appears to be a lack of drug retention, due mainly to low levels of polyglutamylation. A novel association between lack of the retinoblastoma protein and intrinsic MTX resistance has been found. This has been attributed to an increase in DHFR activity, due to an increased rate of transcription of this gene, stimulated by an increase in levels of free E2F, not sequestered by hypophosphorylated retinoblastoma protein.

Original languageEnglish (US)
Pages (from-to)223-226
Number of pages4
JournalOncologist
Volume1
Issue number4
DOIs
StatePublished - Jan 1 1996

Keywords

  • Dihydrofolate reductase
  • Drug resistance
  • Folylpolyglutamate synthetase γ-glutamyl hydrolase
  • Leukemia
  • Methotrexate
  • Sarcoma
  • Trimetrexate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Resistance mechanisms to methotrexate in tumors'. Together they form a unique fingerprint.

  • Cite this

    Bertino, J. R., Göker, E., Gorlick, R., Li, W. W., & Banerjee, D. (1996). Resistance mechanisms to methotrexate in tumors. Oncologist, 1(4), 223-226. https://doi.org/10.1634/theoncologist.1-4-223